The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oligonucleotide (Oligo) Drugs Market Research Report 2025
Synopsis
Oligonucleotides (oligonucleotides for short) drugs are a type of drug molecules based on oligonucleotide structures, used to treat specific diseases. These drugs take advantage of the sequence selectivity, biomolecule recognition, and gene expression regulation of oligonucleotides to regulate the biological processes of diseases.
The global Oligonucleotide (Oligo) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Oligonucleotide (Oligo) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oligonucleotide (Oligo) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oligonucleotide (Oligo) Drugs include Lonis, Biogen, Sarepta, Novartis, Antisense Therapeutics, Akcea, Ruibo Biotechnology, Inois and Therapeutics Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide (Oligo) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide (Oligo) Drugs.
Report Scope
The Oligonucleotide (Oligo) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide (Oligo) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide (Oligo) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonis
Biogen
Sarepta
Novartis
Antisense Therapeutics
Akcea
Ruibo Biotechnology
Inois
Therapeutics Inc.
Sanofi
Segment by Type
siRNA
Antisense Oligonucleotide
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oligonucleotide (Oligo) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oligonucleotide (Oligo) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Oligonucleotides (oligonucleotides for short) drugs are a type of drug molecules based on oligonucleotide structures, used to treat specific diseases. These drugs take advantage of the sequence selectivity, biomolecule recognition, and gene expression regulation of oligonucleotides to regulate the biological processes of diseases.
The global Oligonucleotide (Oligo) Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Oligonucleotide (Oligo) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Oligonucleotide (Oligo) Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Oligonucleotide (Oligo) Drugs include Lonis, Biogen, Sarepta, Novartis, Antisense Therapeutics, Akcea, Ruibo Biotechnology, Inois and Therapeutics Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide (Oligo) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oligonucleotide (Oligo) Drugs.
Report Scope
The Oligonucleotide (Oligo) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide (Oligo) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide (Oligo) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonis
Biogen
Sarepta
Novartis
Antisense Therapeutics
Akcea
Ruibo Biotechnology
Inois
Therapeutics Inc.
Sanofi
Segment by Type
siRNA
Antisense Oligonucleotide
Segment by Application
Hospital
Clinic
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
China Taiwan
Australia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oligonucleotide (Oligo) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oligonucleotide (Oligo) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Oligonucleotide (Oligo) Drugs Market Overview
1.1 Product Overview and Scope of Oligonucleotide (Oligo) Drugs
1.2 Oligonucleotide (Oligo) Drugs Segment by Type
1.2.1 Global Oligonucleotide (Oligo) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 siRNA
1.2.3 Antisense Oligonucleotide
1.3 Oligonucleotide (Oligo) Drugs Segment by Application
1.3.1 Global Oligonucleotide (Oligo) Drugs Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Oligonucleotide (Oligo) Drugs Market Size Estimates and Forecasts
1.4.1 Global Oligonucleotide (Oligo) Drugs Revenue 2019-2030
1.4.2 Global Oligonucleotide (Oligo) Drugs Sales 2019-2030
1.4.3 Global Oligonucleotide (Oligo) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Oligonucleotide (Oligo) Drugs Market Competition by Manufacturers
2.1 Global Oligonucleotide (Oligo) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Oligonucleotide (Oligo) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Oligonucleotide (Oligo) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oligonucleotide (Oligo) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oligonucleotide (Oligo) Drugs, Product Type & Application
2.7 Oligonucleotide (Oligo) Drugs Market Competitive Situation and Trends
2.7.1 Oligonucleotide (Oligo) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oligonucleotide (Oligo) Drugs Players Market Share by Revenue
2.7.3 Global Oligonucleotide (Oligo) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oligonucleotide (Oligo) Drugs Retrospective Market Scenario by Region
3.1 Global Oligonucleotide (Oligo) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Oligonucleotide (Oligo) Drugs Global Oligonucleotide (Oligo) Drugs Sales by Region: 2019-2030
3.2.1 Global Oligonucleotide (Oligo) Drugs Sales by Region: 2019-2024
3.2.2 Global Oligonucleotide (Oligo) Drugs Sales by Region: 2025-2030
3.3 Global Oligonucleotide (Oligo) Drugs Global Oligonucleotide (Oligo) Drugs Revenue by Region: 2019-2030
3.3.1 Global Oligonucleotide (Oligo) Drugs Revenue by Region: 2019-2024
3.3.2 Global Oligonucleotide (Oligo) Drugs Revenue by Region: 2025-2030
3.4 North America Oligonucleotide (Oligo) Drugs Market Facts & Figures by Country
3.4.1 North America Oligonucleotide (Oligo) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Oligonucleotide (Oligo) Drugs Sales by Country (2019-2030)
3.4.3 North America Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oligonucleotide (Oligo) Drugs Market Facts & Figures by Country
3.5.1 Europe Oligonucleotide (Oligo) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Oligonucleotide (Oligo) Drugs Sales by Country (2019-2030)
3.5.3 Europe Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Netherlands
3.6 Asia Pacific Oligonucleotide (Oligo) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Oligonucleotide (Oligo) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Oligonucleotide (Oligo) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Southeast Asia
3.6.9 China Taiwan
3.6.10 Australia
3.7 Latin America Oligonucleotide (Oligo) Drugs Market Facts & Figures by Country
3.7.1 Latin America Oligonucleotide (Oligo) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Oligonucleotide (Oligo) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oligonucleotide (Oligo) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Oligonucleotide (Oligo) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Oligonucleotide (Oligo) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oligonucleotide (Oligo) Drugs Sales by Type (2019-2030)
4.1.1 Global Oligonucleotide (Oligo) Drugs Sales by Type (2019-2024)
4.1.2 Global Oligonucleotide (Oligo) Drugs Sales by Type (2025-2030)
4.1.3 Global Oligonucleotide (Oligo) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Oligonucleotide (Oligo) Drugs Revenue by Type (2019-2030)
4.2.1 Global Oligonucleotide (Oligo) Drugs Revenue by Type (2019-2024)
4.2.2 Global Oligonucleotide (Oligo) Drugs Revenue by Type (2025-2030)
4.2.3 Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Oligonucleotide (Oligo) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Oligonucleotide (Oligo) Drugs Sales by Application (2019-2030)
5.1.1 Global Oligonucleotide (Oligo) Drugs Sales by Application (2019-2024)
5.1.2 Global Oligonucleotide (Oligo) Drugs Sales by Application (2025-2030)
5.1.3 Global Oligonucleotide (Oligo) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Oligonucleotide (Oligo) Drugs Revenue by Application (2019-2030)
5.2.1 Global Oligonucleotide (Oligo) Drugs Revenue by Application (2019-2024)
5.2.2 Global Oligonucleotide (Oligo) Drugs Revenue by Application (2025-2030)
5.2.3 Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Oligonucleotide (Oligo) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Lonis
6.1.1 Lonis Corporation Information
6.1.2 Lonis Description and Business Overview
6.1.3 Lonis Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Lonis Oligonucleotide (Oligo) Drugs Product Portfolio
6.1.5 Lonis Recent Developments/Updates
6.2 Biogen
6.2.1 Biogen Corporation Information
6.2.2 Biogen Description and Business Overview
6.2.3 Biogen Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Biogen Oligonucleotide (Oligo) Drugs Product Portfolio
6.2.5 Biogen Recent Developments/Updates
6.3 Sarepta
6.3.1 Sarepta Corporation Information
6.3.2 Sarepta Description and Business Overview
6.3.3 Sarepta Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Sarepta Oligonucleotide (Oligo) Drugs Product Portfolio
6.3.5 Sarepta Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Corporation Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Novartis Oligonucleotide (Oligo) Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Antisense Therapeutics
6.5.1 Antisense Therapeutics Corporation Information
6.5.2 Antisense Therapeutics Description and Business Overview
6.5.3 Antisense Therapeutics Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Antisense Therapeutics Oligonucleotide (Oligo) Drugs Product Portfolio
6.5.5 Antisense Therapeutics Recent Developments/Updates
6.6 Akcea
6.6.1 Akcea Corporation Information
6.6.2 Akcea Description and Business Overview
6.6.3 Akcea Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Akcea Oligonucleotide (Oligo) Drugs Product Portfolio
6.6.5 Akcea Recent Developments/Updates
6.7 Ruibo Biotechnology
6.6.1 Ruibo Biotechnology Corporation Information
6.6.2 Ruibo Biotechnology Description and Business Overview
6.6.3 Ruibo Biotechnology Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Ruibo Biotechnology Oligonucleotide (Oligo) Drugs Product Portfolio
6.7.5 Ruibo Biotechnology Recent Developments/Updates
6.8 Inois
6.8.1 Inois Corporation Information
6.8.2 Inois Description and Business Overview
6.8.3 Inois Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Inois Oligonucleotide (Oligo) Drugs Product Portfolio
6.8.5 Inois Recent Developments/Updates
6.9 Therapeutics Inc.
6.9.1 Therapeutics Inc. Corporation Information
6.9.2 Therapeutics Inc. Description and Business Overview
6.9.3 Therapeutics Inc. Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Therapeutics Inc. Oligonucleotide (Oligo) Drugs Product Portfolio
6.9.5 Therapeutics Inc. Recent Developments/Updates
6.10 Sanofi
6.10.1 Sanofi Corporation Information
6.10.2 Sanofi Description and Business Overview
6.10.3 Sanofi Oligonucleotide (Oligo) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sanofi Oligonucleotide (Oligo) Drugs Product Portfolio
6.10.5 Sanofi Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oligonucleotide (Oligo) Drugs Industry Chain Analysis
7.2 Oligonucleotide (Oligo) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oligonucleotide (Oligo) Drugs Production Mode & Process
7.4 Oligonucleotide (Oligo) Drugs Sales and Marketing
7.4.1 Oligonucleotide (Oligo) Drugs Sales Channels
7.4.2 Oligonucleotide (Oligo) Drugs Distributors
7.5 Oligonucleotide (Oligo) Drugs Customers
8 Oligonucleotide (Oligo) Drugs Market Dynamics
8.1 Oligonucleotide (Oligo) Drugs Industry Trends
8.2 Oligonucleotide (Oligo) Drugs Market Drivers
8.3 Oligonucleotide (Oligo) Drugs Market Challenges
8.4 Oligonucleotide (Oligo) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Oligonucleotide (Oligo) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Oligonucleotide (Oligo) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Oligonucleotide (Oligo) Drugs Market Competitive Situation by Manufacturers in 2023
Table 4. Global Oligonucleotide (Oligo) Drugs Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Oligonucleotide (Oligo) Drugs Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Oligonucleotide (Oligo) Drugs Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Oligonucleotide (Oligo) Drugs Average Price (US$/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Oligonucleotide (Oligo) Drugs, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Oligonucleotide (Oligo) Drugs, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Oligonucleotide (Oligo) Drugs, Product Type & Application
Table 12. Global Key Manufacturers of Oligonucleotide (Oligo) Drugs, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Oligonucleotide (Oligo) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oligonucleotide (Oligo) Drugs as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Oligonucleotide (Oligo) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Oligonucleotide (Oligo) Drugs Sales by Region (2019-2024) & (K Units)
Table 18. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Region (2019-2024)
Table 19. Global Oligonucleotide (Oligo) Drugs Sales by Region (2025-2030) & (K Units)
Table 20. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Region (2025-2030)
Table 21. Global Oligonucleotide (Oligo) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Region (2019-2024)
Table 23. Global Oligonucleotide (Oligo) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Region (2025-2030)
Table 25. North America Oligonucleotide (Oligo) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Oligonucleotide (Oligo) Drugs Sales by Country (2019-2024) & (K Units)
Table 27. North America Oligonucleotide (Oligo) Drugs Sales by Country (2025-2030) & (K Units)
Table 28. North America Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Oligonucleotide (Oligo) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Oligonucleotide (Oligo) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Oligonucleotide (Oligo) Drugs Sales by Country (2019-2024) & (K Units)
Table 32. Europe Oligonucleotide (Oligo) Drugs Sales by Country (2025-2030) & (K Units)
Table 33. Europe Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Oligonucleotide (Oligo) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Oligonucleotide (Oligo) Drugs Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Oligonucleotide (Oligo) Drugs Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Oligonucleotide (Oligo) Drugs Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Oligonucleotide (Oligo) Drugs Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Oligonucleotide (Oligo) Drugs Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Oligonucleotide (Oligo) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Oligonucleotide (Oligo) Drugs Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Oligonucleotide (Oligo) Drugs Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Oligonucleotide (Oligo) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Oligonucleotide (Oligo) Drugs Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Oligonucleotide (Oligo) Drugs Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Oligonucleotide (Oligo) Drugs Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Oligonucleotide (Oligo) Drugs Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Oligonucleotide (Oligo) Drugs Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Oligonucleotide (Oligo) Drugs Sales (K Units) by Type (2019-2024)
Table 51. Global Oligonucleotide (Oligo) Drugs Sales (K Units) by Type (2025-2030)
Table 52. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Type (2019-2024)
Table 53. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Type (2025-2030)
Table 54. Global Oligonucleotide (Oligo) Drugs Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Oligonucleotide (Oligo) Drugs Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Type (2019-2024)
Table 57. Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Type (2025-2030)
Table 58. Global Oligonucleotide (Oligo) Drugs Price (US$/Unit) by Type (2019-2024)
Table 59. Global Oligonucleotide (Oligo) Drugs Price (US$/Unit) by Type (2025-2030)
Table 60. Global Oligonucleotide (Oligo) Drugs Sales (K Units) by Application (2019-2024)
Table 61. Global Oligonucleotide (Oligo) Drugs Sales (K Units) by Application (2025-2030)
Table 62. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Application (2019-2024)
Table 63. Global Oligonucleotide (Oligo) Drugs Sales Market Share by Application (2025-2030)
Table 64. Global Oligonucleotide (Oligo) Drugs Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Oligonucleotide (Oligo) Drugs Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Application (2019-2024)
Table 67. Global Oligonucleotide (Oligo) Drugs Revenue Market Share by Application (2025-2030)
Table 68. Global Oligonucleotide (Oligo) Drugs Price (US$/Unit) by Application (2019-2024)
Table 69. Global Oligonucleotide (Oligo) Drugs Price (US$/Unit) by Application (2025-2030)
Table 70. Lonis Corporation Information
Table 71. Lonis Description and Business Overview
Table 72. Lonis Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 73. Lonis Oligonucleotide (Oligo) Drugs Product
Table 74. Lonis Recent Developments/Updates
Table 75. Biogen Corporation Information
Table 76. Biogen Description and Business Overview
Table 77. Biogen Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 78. Biogen Oligonucleotide (Oligo) Drugs Product
Table 79. Biogen Recent Developments/Updates
Table 80. Sarepta Corporation Information
Table 81. Sarepta Description and Business Overview
Table 82. Sarepta Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 83. Sarepta Oligonucleotide (Oligo) Drugs Product
Table 84. Sarepta Recent Developments/Updates
Table 85. Novartis Corporation Information
Table 86. Novartis Description and Business Overview
Table 87. Novartis Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 88. Novartis Oligonucleotide (Oligo) Drugs Product
Table 89. Novartis Recent Developments/Updates
Table 90. Antisense Therapeutics Corporation Information
Table 91. Antisense Therapeutics Description and Business Overview
Table 92. Antisense Therapeutics Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 93. Antisense Therapeutics Oligonucleotide (Oligo) Drugs Product
Table 94. Antisense Therapeutics Recent Developments/Updates
Table 95. Akcea Corporation Information
Table 96. Akcea Description and Business Overview
Table 97. Akcea Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 98. Akcea Oligonucleotide (Oligo) Drugs Product
Table 99. Akcea Recent Developments/Updates
Table 100. Ruibo Biotechnology Corporation Information
Table 101. Ruibo Biotechnology Description and Business Overview
Table 102. Ruibo Biotechnology Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 103. Ruibo Biotechnology Oligonucleotide (Oligo) Drugs Product
Table 104. Ruibo Biotechnology Recent Developments/Updates
Table 105. Inois Corporation Information
Table 106. Inois Description and Business Overview
Table 107. Inois Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 108. Inois Oligonucleotide (Oligo) Drugs Product
Table 109. Inois Recent Developments/Updates
Table 110. Therapeutics Inc. Corporation Information
Table 111. Therapeutics Inc. Description and Business Overview
Table 112. Therapeutics Inc. Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 113. Therapeutics Inc. Oligonucleotide (Oligo) Drugs Product
Table 114. Therapeutics Inc. Recent Developments/Updates
Table 115. Sanofi Corporation Information
Table 116. Sanofi Description and Business Overview
Table 117. Sanofi Oligonucleotide (Oligo) Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 118. Sanofi Oligonucleotide (Oligo) Drugs Product
Table 119. Sanofi Recent Developments/Updates
Table 120. Key Raw Materials Lists
Table 121. Raw Materials Key Suppliers Lists
Table 122. Oligonucleotide (Oligo) Drugs Distributors List
Table 123. Oligonucleotide (Oligo) Drugs Customers List
Table 124. Oligonucleotide (Oligo) Drugs Market Trends
Table 125. Oligonucleotide (Oligo) Drugs Market Drivers
Table 126. Oligonucleotide (Oligo) Drugs Market Challenges
Table 127. Oligonucleotide (Oligo) Drugs Market Restraints
Table 128. Research Programs/Design for This Report
Table 129. Key Data Information from Secondary Sources
Table 130. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Oligonucleotide (Oligo) Drugs
Figure 2. Global Oligonucleotide (Oligo) Drugs Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Oligonucleotide (Oligo) Drugs Market Share by Type in 2023 & 2030
Figure 4. siRNA Product Picture
Figure 5. Antisense Oligonucleotide Product Picture
Figure 6. Global Oligonucleotide (Oligo) Drugs Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Oligonucleotide (Oligo) Drugs Market Share by Application in 2023 & 2030
Figure 8. Hospital
Figure 9. Clinic
Figure 10. Global Oligonucleotide (Oligo) Drugs Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 11. Global Oligonucleotide (Oligo) Drugs Market Size (2019-2030) & (US$ Million)
Figure 12. Global Oligonucleotide (Oligo) Drugs Sales (2019-2030) & (K Units)
Figure 13. Global Oligonucleotide (Oligo) Drugs Average Price (US$/Unit) & (2019-2030)
Figure 14. Oligonucleotide (Oligo) Drugs Report Years Considered
Figure 15. Oligonucleotide (Oligo) Drugs Sales Share by Manufacturers in 2023
Figure 16. Global Oligonucleotide (Oligo) Drugs Revenue Share by Manufacturers in 2023
Figure 17. The Global 5 and 10 Largest Oligonucleotide (Oligo) Drugs Players: Market Share by Revenue in 2023
Figure 18. Oligonucleotide (Oligo) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 19. Global Oligonucleotide (Oligo) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 20. North America Oligonucleotide (Oligo) Drugs Sales Market Share by Country (2019-2030)
Figure 21. North America Oligonucleotide (Oligo) Drugs Revenue Market Share by Country (2019-2030)
Figure 22. United States Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 23. Canada Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 24. Europe Oligonucleotide (Oligo) Drugs Sales Market Share by Country (2019-2030)
Figure 25. Europe Oligonucleotide (Oligo) Drugs Revenue Market Share by Country (2019-2030)
Figure 26. Germany Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. France Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 28. U.K. Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 29. Italy Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. Netherlands Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. Asia Pacific Oligonucleotide (Oligo) Drugs Sales Market Share by Region (2019-2030)
Figure 32. Asia Pacific Oligonucleotide (Oligo) Drugs Revenue Market Share by Region (2019-2030)
Figure 33. China Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Japan Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 35. South Korea Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 36. India Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Southeast Asia Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. China Taiwan Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. Australia Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Latin America Oligonucleotide (Oligo) Drugs Sales Market Share by Country (2019-2030)
Figure 41. Latin America Oligonucleotide (Oligo) Drugs Revenue Market Share by Country (2019-2030)
Figure 42. Mexico Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Brazil Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Argentina Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Oligonucleotide (Oligo) Drugs Sales Market Share by Country (2019-2030)
Figure 46. Middle East & Africa Oligonucleotide (Oligo) Drugs Revenue Market Share by Country (2019-2030)
Figure 47. Turkey Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. UAE Oligonucleotide (Oligo) Drugs Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Global Sales Market Share of Oligonucleotide (Oligo) Drugs by Type (2019-2030)
Figure 51. Global Revenue Market Share of Oligonucleotide (Oligo) Drugs by Type (2019-2030)
Figure 52. Global Oligonucleotide (Oligo) Drugs Price (US$/Unit) by Type (2019-2030)
Figure 53. Global Sales Market Share of Oligonucleotide (Oligo) Drugs by Application (2019-2030)
Figure 54. Global Revenue Market Share of Oligonucleotide (Oligo) Drugs by Application (2019-2030)
Figure 55. Global Oligonucleotide (Oligo) Drugs Price (US$/Unit) by Application (2019-2030)
Figure 56. Oligonucleotide (Oligo) Drugs Value Chain
Figure 57. Oligonucleotide (Oligo) Drugs Production Process
Figure 58. Channels of Distribution (Direct Vs Distribution)
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
